Clofarabine

Nature Reviews Drug Discovery

Volumn 4, Issue 5, 2005, Pages 369-370

  Pui, Ching Hon ^a   Jeda, Sima ^a   Kirkpatrick, Peter ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; AZACITIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; CYTOTOXIC AGENT; FLUDARABINE; GEMCITABINE; GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; NELARABINE; NEW DRUG; PURINE NUCLEOSIDE DERIVATIVE; VALPROIC ACID; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RELAPSE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MYELODYSPLASIA; MYELOID LEUKEMIA; NEUROTOXICITY; PRIORITY JOURNAL; T CELL LEUKEMIA;

ADENINE NUCLEOTIDES; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE;

EID: 18944392700     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1724     Document Type: Article

References (18)

1. Pui, C. H. et al. Acute lymphoblastic leukemia. N. Engl. J. Med. 350, 1535-1548 (2004).
2. Faderl. S. et al. The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer Res. 31 Mar 2005 (doi: 10.1002/cncr.21005).
3. Montgomery J. A. et al. Synthesis and biologic activity of 22-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J. Med. Chem. 35, 397-401 (1992).
4. Parker, W. B. et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 51, 2386-2394 (1991).
5. Carson, D. A. et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-22-arabino-fluoro-22-deoxy-adenosine. Proc. Natl Acad. Sci. USA 89, 2970-2974 (1992).
6. FDA labelling information [online], http://www.fda.gov/cder/foi/label/2004/021673lbl.pdf (2004).
7. Jeha, S. et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103, 784-789 (2004).
8. Kantarjian, H. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379-2386 (2003).
9. Pui, C. H. et al. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am. Soc Hematol. Educ. Program) 118-145 (2004).
10. Stone, R. M. et al. Acute myeloid leukemia. Hematology (Am. Soc. Hematol. Educ. Program) 98-117 (2004).
11. Wassmann, B. et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CST1571ADE 10). Ann. Hematol. 82, 716-720 (2003).
12. Thomas, D. A. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396-4407 (2004).
13. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics, in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
14. Kantarjian, H. M. et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 21, 1167-1173 (2003).
15. Burnett, A. K. et al. A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 104, 248a (2004).
16. Faderl, S. et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105, 940-947 (2005).
17. Faderl, S. et al. Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) = age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 104, 250a (2004).
18. Faderl, S. et al. Phase I study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML). Blood 104, 501a (2004).